Nora Kim

Articles by Nora Kim (112)

• Night Eating Syndrome and Weight Loss: How to Recognize the DSM-5 Pattern, Distinguish It From Snacking or Bingeing, and Actually Treat It

  Night Eating Syndrome affects 1.5% of adults and up to 14% of bariatric candidates. It's a DSM-5-recognized circadian eating pattern — distinct from binge eating or snacking. Sertraline 200 mg (Allison 2018) and CBT-NES have real evidence. Here's how to recognize it and what actually works.

• Cardiovascular Disease and Weight Loss: What SELECT, Look AHEAD, and the STEP-HFpEF Trials Actually Show About MACE, MI, and Stroke Risk

  SELECT showed semaglutide 2.4 mg cut major cardiac events 20% in patients with heart disease and obesity. Look AHEAD did not hit its primary endpoint at group level, but ≥10% loss did. Here's what the trials actually show about weight loss and cardiovascular risk.

• Type 2 Diabetes Remission via Weight Loss: What DiRECT, DIADEM-I, and STAMPEDE Actually Show About the 15 kg Threshold

  DiRECT put 46% of participants into remission at 1 year and 36% at 2 years with primary-care VLCD. Here's the ADA/EASD definition, the ~15 kg threshold, and how DIADEM-I and STAMPEDE fit.

• Leptin, Ghrelin, and Hunger Hormones: What Actually Drives Appetite While You're Losing Weight

  Sumithran 2011 showed leptin stays low and ghrelin stays high for at least 12 months after a diet. Here's what the six appetite hormones actually do and how to work with, not against, them.

• The Diabetes Prevention Program (DPP): Why the 7% Weight Loss / 150 Minute Standard Still Works 22 Years Later

  The Diabetes Prevention Program showed that a 7% body-weight loss plus 150 minutes/week of moderate activity cut incident type 2 diabetes by 58% in adults with prediabetes — nearly twice the reduction produced by metformin. Two decades of follow-up in the DPPOS, Finnish DPS, and Da Qing cohorts show the benefit holds. This guide covers who qualifies, how to enroll in a CDC-recognized National DPP, and how the program layers with metformin, GLP-1 medications, and bariatric surgery.

• Bariatric Post-Op Vitamin and Nutrition Protocol: The ASMBS 2020 Standard for Sleeve, Bypass, SADI, and Revisions

  The ASMBS 2020 lifetime supplement stack after sleeve gastrectomy, gastric bypass, and duodenal switch — dose by procedure, timing rules, standardized labs, and when to go to the ER.

• Gut Microbiome and Weight Loss: What Firmicutes, Bacteroidetes, and Akkermansia Actually Do to Body Weight

  The gut microbiome shifts modestly with body weight, but the popular story — that a probiotic pill or a Firmicutes-to-Bacteroidetes ratio predicts obesity — is not what the evidence supports. Diet diversity, prebiotic fiber, and fermented foods produce the largest reproducible microbiome changes, while probiotic supplements and fecal microbiota transplant show small, inconsistent effects on human body weight.

• Rybelsus (Oral Semaglutide) for Weight Loss: What the 3, 7, and 14 mg Tablets Actually Do to the Scale

  Rybelsus is the tablet form of semaglutide — the same molecule as Ozempic and Wegovy, delivered orally with an absorption-enhancer called SNAC. At its 14 mg maintenance dose it produces roughly 4 to 4.5 percent weight loss, well below Wegovy's 15 percent, but it gained a 2025 FDA cardiovascular-risk-reduction indication (SOUL) and a higher-dose oral formulation for obesity (OASIS-4, 50 mg) is under FDA review. Rybelsus requires a strict fasting window and 4 oz of plain water, and it is not first-line for weight loss.

• Next Generation Weight Loss Drugs: Where Retatrutide, Orforglipron, CagriSema, Survodutide, and MariTide Actually Stand in 2026

  The post-tirzepatide anti-obesity pipeline is real and the Phase 2 signals are extraordinary — retatrutide about 24 percent at 48 weeks, MariTide about 20 percent with monthly dosing, CagriSema about 22.7 percent, orforglipron about 14.7 percent orally, survodutide about 19 percent. But none of these five drugs is FDA-approved for chronic weight management as of publication and Phase 3 outcome data land between mid-2026 and 2028. Wegovy and Zepbound remain the standard of care in 2026, and unregulated research-chemical retatrutide sold online is not the drug from the trials.

• Insulin Therapy and Weight in Type 2 Diabetes: Why Basal Insulin Causes Weight Gain and How to Mitigate It

  Basal insulin adds about 2 to 4 kg per year on average in type 2 diabetes — mostly visceral — through glucosuria recapture, defensive snacking against hypoglycaemia, and direct anabolic action. Modern ADA 2024 ordering pushes insulin to third or fourth line behind metformin, GLP-1 agonists, and SGLT2 inhibitors, and layering rather than substituting prevents most of the weight-gain trade-off.

• Continuous Glucose Monitors for Weight Loss: What Stelo, Lingo, Dexcom, and FreeStyle Libre Actually Tell You

  A continuous glucose monitor measures interstitial glucose every 1 to 5 minutes. In type 2 and type 1 diabetes it clearly improves outcomes and is standard of care. For weight loss in adults without diabetes the RCT signal is small but real — roughly 1 to 2 kg over 3 to 6 months when paired with behavioural coaching. Stelo (Dexcom, OTC 2024) and Lingo (Abbott, US launch 2024) made CGMs mainstream, and glucose spikes in non-diabetics are mostly normal physiology, not a weight-loss failure signal.

• Saxenda (Liraglutide 3 mg) for Weight Loss: Where the First FDA-Approved GLP-1 Fits After Wegovy and Zepbound

  Saxenda (liraglutide 3 mg) delivers roughly 6–8% weight loss over 56 weeks — the FDA benchmark that opened the modern obesity-drug era in 2014, but roughly 40% of what semaglutide 2.4 mg delivers and 30% of tirzepatide 15 mg. It remains the only GLP-1 FDA-approved for adolescents 12+ and holds a legitimate niche when Wegovy or Zepbound are unavailable, contraindicated, or uncovered.

• Resmetirom (Rezdiffra) for MASH: What the First FDA-Approved Fatty Liver Drug Means for Weight and Fibrosis

  Resmetirom (Rezdiffra) is the first FDA-approved drug for MASH — the inflammatory stage of fatty liver disease. In MAESTRO-NASH, roughly 26 to 30 percent of adults achieved MASH resolution and 24 to 26 percent achieved fibrosis improvement at 52 weeks, versus about 10 to 14 percent on placebo. It is an additive, not a replacement, therapy — the 5 to 10 percent weight loss that reverses steatosis remains the foundation.

• Orlistat (Xenical, Alli) for Weight Loss: How the Only FDA-Approved Lipase Inhibitor Works and When It Still Makes Sense

  Orlistat (Xenical prescription, Alli OTC) blocks about 30% of dietary fat absorption and delivers roughly 3–4 kg placebo-adjusted weight loss at one year — about a quarter of what Wegovy achieves and a fifth of Zepbound — but it is the only OTC option, the only weight-loss drug with no CNS profile, an FDA-approved pediatric option since 2003, and the only pharmacologic weight-loss drug with a four-year outcomes trial (XENDOS) showing a 37% relative reduction in progression to type 2 diabetes.

• Compounded Semaglutide and Tirzepatide in 2026: Safety, Legality, and Quality After the Shortage Ended

  Compounded semaglutide and tirzepatide were legal during the 2022–2024 FDA shortages, but both drugs came off the shortage list in late 2024 and mass-produced compounded copies are no longer legal under Section 503A except for narrow clinical-need exceptions. Here is the honest 2026 picture on safety, legality, quality, and how to evaluate a compounding pharmacy.

• SGLT2 Inhibitors and Weight: What Jardiance, Farxiga, and Invokana Actually Do to the Scale

  SGLT2 inhibitors — empagliflozin (Jardiance), dapagliflozin (Farxiga), canagliflozin (Invokana) — produce about 1.8 kg of placebo-adjusted fat-mass loss on average, roughly half of what a GLP-1 delivers. They earn first-line status in type 2 diabetes with heart failure or chronic kidney disease because of cardiorenal outcomes, not because of the scale.

• Qsymia (Phentermine-Topiramate) for Weight Loss: How the Combination Works and Why It Delivers More Than Phentermine Alone

  Qsymia (phentermine-topiramate) delivers roughly 9–11% placebo-adjusted weight loss over 56 weeks — best-in-class of the pre-GLP-1 orals, about 80% of semaglutide 2.4 mg and roughly half of tirzepatide 15 mg — with a REMS teratogenicity program, a real cognitive burden inherited from topiramate, and a DEA Schedule IV constraint inherited from phentermine.

• Menopausal Hormone Therapy and Weight: What Estrogen Does to Body Composition

  Menopausal hormone therapy is not a weight-loss drug — but it also does not meaningfully cause weight gain. What the trials actually show on estrogen, body composition, T2D risk, and the timing hypothesis that reframed the WHI.

• Contrave (Naltrexone-Bupropion) for Weight Loss: What It Does, Who It Fits, and Where It Falls Short

  Contrave (naltrexone-bupropion) delivers roughly 5–6% placebo-adjusted weight loss over 56 weeks — clinically useful, roughly half of semaglutide 2.4 mg and one-third of tirzepatide 15 mg — with a real seizure risk, an opioid-antagonism liability, and a boxed suicidal-behaviour warning inherited from bupropion.

• TRT and Weight: Fat Mass, Lean Mass, and What TRAVERSE Changed

  Testosterone replacement therapy is a body-composition-shift drug, not a weight-loss drug. Expect roughly 1.7 kg of fat loss and 1.9 kg of lean-mass gain in confirmed hypogonadism — and after TRAVERSE 2023, the older heart-safety concern no longer holds in typical hypogonadal men.

• Statins and Weight: What They Do, What They Don't, and Who Should Be On One

  Statins do not meaningfully cause weight gain. The muscle-symptom scare is largely nocebo, the diabetes signal is small, and the mortality benefit is real. What the trial evidence actually says — and why do not stop your statin because you lost weight.

• Metformin and Weight: What It Does, What It Doesn't, and When It Helps

  Metformin is not a weight-loss drug. It produces about 2 to 3 kg of placebo-adjusted weight loss on average, plateaus by six months, and comes back on discontinuation — but it earns its place in prediabetes, PCOS, antipsychotic add-on, and type 2 diabetes for very specific reasons.

• Beta Blockers and Weight: Why the Scale Creeps and What Actually Helps

  Beta blockers cause a small but real weight gain — about 1 to 2 kg on average — through suppressed thermogenesis and blunted lipolysis. The effect is drug-specific: propranolol and atenolol are the worst; carvedilol is intermediate; nebivolol is essentially weight-neutral. Do not stop your beta blocker to fix the scale.

• Opioids and Weight Changes: Chronic Pain, Long-Term Use, and What Helps

  Long-term opioids don't reliably drive scale weight, but three linked mechanisms do — endocrine, constipation, and de-conditioning — while methadone maintenance adds 5 to 15 kg. The honest picture and what actually helps.

• Breast Cancer Survivor Weight: Aromatase Inhibitors, Tamoxifen, and What Helps

  Adjuvant endocrine therapy drives 2 to 5 kg of survivor weight gain over 5 to 10 years — mostly via joint pain, activity loss, and treatment-induced menopause. The honest picture and what actually helps, always alongside your oncology team.

• Dumping Syndrome After Bariatric Surgery: Early, Late, and What Helps

  Early dumping is sweats and cramps after meals. Late dumping is hypoglycemia 1–3 hours later. The honest food, drug, and re-operation picture.

• Antipsychotics and Weight Gain: Olanzapine, Clozapine, and What Helps

  Antipsychotics vary widely in weight effect. Olanzapine and clozapine drive the most; aripiprazole and lurasidone the least. The honest drug-by-drug picture and what actually helps.

• Corticosteroids and Weight Gain: What Prednisone Does and What Helps

  Prednisone causes weight gain through appetite, fluid, and central fat. The honest dose-time picture, what actually helps, and when to ask for a taper.

• Weight Loss for Older Adults: BMI, Function, Honest Playbook

  After 65, BMI rules shift, muscle and bone come first, and faster isn't safer. The honest function-first playbook for losing weight as you age.

• Hyperthyroidism and Weight Loss: Graves', Treatment, Rebound

  Hyperthyroidism speeds weight loss — and most patients regain past baseline once treated. What causes the loss, the rebound, and what helps.

• Lupus (SLE) and Weight Loss: Steroids, Flares, and What Helps

  Most lupus weight gain is driven by steroids and flare cycles, not the disease itself. What hydroxychloroquine, biologics, diet, and exercise actually change.

• Hypoglycemia and Weight Loss: Spot, Treat, and Prevent It

  Low blood sugar is the most common safety issue in weight-loss care. Insulin, GLP-1, post-bariatric, fasting — what helps, what doesn't.

• Cushing's Syndrome and Weight Gain: Symptoms, Tests, What Helps

  Cushing's is rare but real. The symptoms, how it's diagnosed, and what actually helps the iatrogenic and endogenous forms.

• Type 1 Diabetes and Weight Loss: Insulin, CGM, and What Helps

  Intensive insulin therapy adds 4–5 kg in T1D. CGM, hybrid closed-loop, metformin, and exercise tactics that work without hypoglycemia.

• Sarcopenia and Weight Loss: How to Protect Muscle as You Age

  Sarcopenia speeds up after 60 and accelerates on GLP-1s. Protein, resistance training, and what actually preserves muscle through weight loss.

• Multiple Sclerosis and Weight Loss: Diet, Steroids, Plan

  MS, steroids, and DMTs reshape weight in ways generic plans miss. Diet, mobility-aware exercise, and what actually helps.

• Psoriatic Arthritis and Weight Loss: How Body Weight Changes PsA

  Obesity reduces biologic response in PsA. A 16% weight loss produced ACR responses without drug change. Here is the evidence and a 5-step plan.

• Low Testosterone and Weight Loss: TRT vs Weight Loss

  Visceral fat lowers testosterone and weight loss raises it. Evidence on when TRT helps, when it doesn't, and a 5-step plan.

• Hashimoto's Thyroiditis and Weight Loss: TSH, Diet, and What Helps

  Hashimoto's is the #1 cause of hypothyroidism. Treatment, diet, and TSH targets that actually move the scale — without the supplement myths.

• Prediabetes and Weight Loss: How a 7% Loss Cuts Diabetes Risk in Half

  About 96M US adults have prediabetes. A 5–7% weight loss cuts type 2 diabetes risk by ~58%. Here is the evidence and a 5-step plan.

• Lymphedema and Weight Loss: What Actually Helps Swelling

  Weight loss can meaningfully reduce lymphedema swelling. Here is what the evidence says about diet, exercise, compression, and surgery.

• IBD and Weight Loss: Crohn's, Ulcerative Colitis, and What Helps

  Obese-IBD blunts biologic response. Here is the diet, dosing, and GLP-1 evidence plus a 5-step plan from a clinician's lens.

• Rheumatoid Arthritis and Weight Loss: Treatment Response

  Obesity blunts RA biologic response by ~40%. Here is the link, a 5-step plan, and what bariatric and GLP-1 evidence shows.

• Osteoporosis and Weight Loss: Protect Your Bones While You Lose

  Aggressive weight loss can cost bone. Here is the dose-response, a 5-step bone-protection protocol, and when to ask for a DEXA.

• IIH and Weight Loss: How Losing Weight Reverses Pseudotumor Cerebri

  IIH is the most clearly weight-driven neurology condition. Here is the Sinclair RCT, IIHTT data, and what 5–10% loss can do for headache and vision.

• Hidradenitis Suppurativa and Weight Loss: How Losing Weight Reduces Flares

  Obesity is one of the strongest drivers of HS flares. Here is the dose-response, a 5-step plan, and what bariatric and GLP-1 data show.

• COPD and Weight Loss: When to Lose, When to Gain, What Helps

  COPD weight management is U-shaped: obesity worsens dyspnea; cachexia worsens survival. Here is the honest framework and what each scenario needs.

• Psoriasis and Weight Loss: How Losing Weight Clears Skin

  Obesity worsens psoriasis. Here is the dose-response, a 5-step protocol, and what the low-energy-diet RCT and GLP-1 cohorts actually show.

• Pancreatitis and Weight Loss: GLP-1 Safety and Gallstone Risk

  Ozempic and Mounjaro carry a pancreatitis warning. Here is what the trial data show, the gallstone-pancreatitis link, and a 5-step safety protocol.

• Migraine and Weight Loss: How Body Weight Affects Headaches

  Obesity raises chronic migraine risk 5×. Here is the dose-response, a 5-step prevention protocol, and what topiramate and GLP-1 data show.

• Lipedema and Weight Loss: How to Tell It Apart From Obesity

  Lipedema is a distinct lymphatic-fat disorder, not obesity. Here is how to tell them apart and the conservative-care ladder that actually helps.

• Dementia, Alzheimer's, and Weight Loss: What Body Weight Has to Do With Your Brain

  Midlife obesity raises dementia risk ~70%. Here is the dose-response, a 5-step brain-protection protocol, and what GLP-1 and lifestyle data show.

• Stroke and Weight Loss: Cutting Risk Before and After a Stroke

  Body weight is a leading modifiable stroke risk factor. Here is the dose-response, a 5-step prevention protocol, and what GLP-1 and bariatric data show.

• Metabolic Syndrome and Weight Loss: Reverse All 5 Markers

  Losing 7 percent body weight reverses metabolic syndrome in about half of adults. Here is the ATP III diagnosis, the dose-response, and the 5-step protocol.

• Atrial Fibrillation and Weight Loss: 10% Loss Can Reverse AFib

  Losing 10 percent of body weight makes adults 6 times more likely to stay AFib-free. Here is the dose-response, the 5-step protocol, and what GLP-1 data show.

• Asthma and Weight Loss: Better Breathing and Fewer Attacks

  Obesity is a top risk factor for adult-onset asthma. Here is the dose-response, a 5-step protocol, and what bariatric and GLP-1 data show.

• Ozempic Face: Why GLP-1 Weight Loss Changes Your Face

  Ozempic face is normal facial-fat loss made faster. Here's why it happens, who's most at risk, and how to prevent or treat it honestly.

• Heart Failure and Weight Loss: How Much to Lose to Help Your Heart

  Modest weight loss improves symptoms in HFpEF, and GLP-1 medications now have direct trial data. Here is the dose-response, protocol, and obesity paradox explained.

• Cancer and Weight Loss: How Body Weight Drives Cancer Risk

  Obesity raises risk for 13 cancers and is the second-leading preventable cause in the US. Here is the dose-response, prevention protocol, and bariatric and GLP-1 data.

• Gout and Weight Loss: Why Rapid Loss Can Trigger Attacks

  Long-term weight loss cuts gout risk by 30 to 50 percent, but rapid loss can trigger attacks. Here is how to lose weight without flaring.

• Erectile Dysfunction and Weight Loss: How 10% Restores Function

  Losing 5 to 10 percent of body weight reverses ED in roughly 1 in 3 men with obesity. Here is the protocol, the timeline, and what GLP-1 medications change.

• Chronic Kidney Disease (CKD) and Weight Loss: How Much to Lose to Protect Your Kidneys

  Losing 5–10% of body weight slows CKD progression and lowers proteinuria. Here's how much to lose, and how semaglutide changes the math.

• Back Pain and Weight Loss: How Much to Lose to Cut Low Back Pain

  Losing 5 to 10 percent of body weight cuts lower back pain in most adults. Here is how much to lose, why it works, and the 5-step protocol.

• Knee Osteoarthritis and Weight Loss: How Much to Lose to Cut Pain

  Each pound lost takes about 4 pounds of force off your knees during walking. Here is how a 5 to 10 percent loss plus the right exercise cuts arthritis pain 30 to 50 percent.

• GERD and Weight Loss: How Much to Lose to Calm Heartburn

  A 5 to 10 percent body-weight loss cuts reflux symptoms in roughly 80 percent of people. Here is the BMI dose-response, the 6-step protocol, and the sleeve-vs-bypass decision that quietly changes the answer.

• Gallstones and Weight Loss: Why Rapid Loss Triggers Them and How to Prevent Them

  Rapid weight loss can trigger gallstones in 10 to 25 percent of people. Here is why it happens, who is at highest risk, and the 5 evidence-based steps that prevent them.

• Cholesterol and Weight Loss: How Much to Lose to Drop Your LDL

  Every kilogram of weight lost drops LDL by roughly 2 mg/dL and triglycerides by about 7 mg/dL, and a 5 to 10 percent body-weight loss is usually enough to cross an ACC/AHA risk threshold. Here is the dose-response, the 5-step protocol, and how to think about statins and GLP-1s.

• Sleep Apnea (OSA) and Weight Loss: Why It Matters and How Much to Lose

  Obstructive sleep apnea affects an estimated 1 in 4 adults with overweight or obesity and worsens with weight gain — and weight loss is one of the few interventions that genuinely improves it. Here is what OSA is, how it is diagnosed, how much weight loss reduces it, and what the new GLP-1 / tirzepatide data really shows.

• Fatty Liver Disease (NAFLD / MASLD) and Weight Loss: How Much You Need to Lose to Reverse It

  Fatty liver disease (renamed MASLD in 2023) affects roughly 1 in 3 US adults and is silently driven by excess body fat, insulin resistance, and added sugar. The good news: a 5 to 10 percent body-weight loss reverses the fat in most people, and a 10 percent loss reverses fibrosis in many. Here is what the disease actually is, how it is diagnosed, and the evidence-based weight-loss path that works.

• High Blood Pressure and Weight Loss: How Much to Lose to Drop Your Numbers

  Weight loss is one of the most reliable non-drug ways to lower blood pressure: roughly 1 mmHg of systolic drop per kilogram lost, with a 5 to 10 percent body-weight loss often enough to drop a stage. Here is what the evidence shows, the 5-lever protocol that works, and how to think about medications and DASH.

• GLP-1 Microdosing: What It Is, Who Does It, and What the Evidence Says

  GLP-1 microdosing uses 1/4 to 1/8 of the labeled semaglutide or tirzepatide dose, usually for cost, side-effect tolerance, recomposition, or maintenance. Here's what the evidence actually shows, what it does not, and how to think about it honestly in 2026.

• Constipation During Weight Loss: Causes, Fixes, and When to See a Doctor

  Constipation during weight loss usually comes from one of four causes — less food volume, less fiber, less water, or slower gut motility from a GLP-1 — and resolves with a 5-step protocol. Most cases don't need a laxative; some need a doctor.

• Rebound Weight Gain After Stopping GLP-1: What to Expect and How to Minimize It

  In the STEP-1 extension, patients regained about two-thirds of lost weight within 1 year of stopping semaglutide — but planned tapering, lifestyle anchoring, and maintenance dosing each meaningfully change the outcome.

• Insulin Resistance and Weight Loss: How to Recognize It and What Actually Reverses It

  Insulin resistance is the most common metabolic reason adults struggle to lose weight. This guide explains how to recognize it, how it is tested, and the four evidence-based approaches that reliably reverse it.

• Set Point Theory: Why Your Body Defends a Higher Weight (and What To Do About It)

  Your body actively defends a 'set point' weight through metabolic and hunger changes. This guide explains the leptin and ghrelin biology, what shifts the set point downward (slowly), and what doesn't.

• Menopause and Weight Loss: What Changes and What to Do About It

  Menopause shifts where fat is stored and slows muscle maintenance; here's what actually changes, what doesn't, and the realistic playbook for losing weight through perimenopause and beyond.

• GLP-1 Cost and Insurance Coverage in 2026: Ozempic, Wegovy, Mounjaro, Zepbound

  What GLP-1 weight loss medications actually cost in 2026, what insurance covers, manufacturer savings programs, compound vs brand pricing, and how telehealth changes the math.

• Diabetes and Weight Loss: A Type 2 Reversal-Focused Guide

  Type 2 diabetes responds strongly to weight loss; this guide explains the remission thresholds, what to eat, how GLP-1 medications and metformin fit in, and what to expect realistically.

• Thyroid and Weight Loss: What Hypothyroidism Actually Does to Your Metabolism

  Untreated hypothyroidism modestly lowers resting metabolism — roughly 5 to 10 percent, not the ruined-metabolism myth — and once TSH is in range on levothyroxine, weight loss follows normal diet-and-exercise rules.

• PCOS and Weight Loss: A Realistic, Evidence-Based Guide

  PCOS makes weight loss harder through insulin resistance and androgen excess, but a 5–10% body-weight loss meaningfully improves cycles, fertility, and metabolic markers — here is what actually works for diet, exercise, sleep, and medication.

• Body Fat Percentage: How to Measure It and Healthy Ranges

  What body fat percentage actually means, healthy ranges by age and sex, how to measure it accurately at home or in a clinic, and why it complements (but doesn't replace) BMI.

• Non-Surgical Weight Loss Procedures Compared: ESG vs Gastric Balloon vs Gastric Band

  Side-by-side comparison of endoscopic sleeve gastroplasty (ESG), intragastric balloon, and adjustable gastric banding — expected weight loss, reversibility, recovery, BMI eligibility, and how to choose.

• Bariatric Surgery vs GLP-1 Medications: Which Is Right For You?

  An honest, evidence-based comparison of bariatric surgery and GLP-1 medications — average weight loss, durability, cost, side effects, and who each is best for.

• Bariatric Surgery Cost and Insurance Coverage: What Weight Loss Surgery Really Costs

  What gastric bypass, sleeve, band, ESG, and gastric balloon actually cost in the U.S. — self-pay ranges, what insurance covers, BMI requirements, the approval timeline, and how to handle a denial.

• GLP-1 Weight Loss Medications Compared (2026): Ozempic vs Wegovy vs Mounjaro vs Zepbound

  Head-to-head comparison of Ozempic, Wegovy, Mounjaro, and Zepbound — average 15–22% body-weight loss at 68–72 weeks, dosing schedules, side-effect profiles, and 2026 U.S. list prices.

• Bariatric Surgery Types Compared (2026): Gastric Bypass vs Sleeve vs Band vs ESG

  Side-by-side comparison of gastric bypass, sleeve, band, ESG, balloon, and revision — typical 1-year weight loss ranges from 10% to 30% of total body weight, with reversibility, recovery time, and cost.

• Mounjaro for Weight Loss: 15-21% Loss in 72-Week Trials

  Mounjaro (tirzepatide) is a prescription GIP/GLP-1 injection that produced 15-21% average weight loss over 72 weeks in the SURMOUNT trials.

• Best Natural Appetite Suppressant: What Actually Works

  The best natural appetite suppressant is glucomannan fiber — backed by clinical trials. Stimulants fade fast and none match prescription GLP-1s.

• Zepbound for Weight Loss: Cost, Results, Side Effects

  Zepbound (tirzepatide) for chronic weight management: average results, monthly cost, side effects, candidacy, and how it compares to other GLP-1 drugs.

• Ozempic vs Wegovy: Key Differences Explained

  Ozempic and Wegovy share the same drug, semaglutide, but differ in approved use, dosing, cost, and insurance. Here's what that means for weight loss.

• Endoscopic Sleeve Gastroplasty: Procedure & Eligibility

  Who qualifies for endoscopic sleeve gastroplasty (ESG)? BMI criteria, candidacy rules, expected results, costs, and how it compares to bariatric surgery.

• Ozempic for Weight Loss: What to Know

  Ozempic is an FDA-approved diabetes medication widely used off-label for weight loss. Learn how it works, what results to expect, how it compares to Wegovy, and what to discuss with your doctor.

• Loose Skin After Weight Loss: What Actually Helps (2026)

  Loose skin after losing 50+ pounds is common — here's what actually helps tighten it, what doesn't, and when body-contouring surgery makes sense.

• Wegovy for Weight Loss

  Wegovy is the brand name for semaglutide approved for chronic weight management; learn how it works, expected results, side effects, cost, and how it compares to Ozempic and Zepbound.

• Semaglutide vs Tirzepatide

  Compare semaglutide and tirzepatide for weight loss, including expected results, side effects, cost, and who each option fits best.

• Weight Loss Supplements Overview

  A balanced overview of weight loss supplements, how they are regulated, and what evidence exists.

• Weight Loss Injections Near Me

  Learn what people mean by weight loss injections, how local and telehealth options differ, and what questions to ask a provider.

• Weight Loss Drug Safety

  Safety essentials for weight loss medications, including side effects, monitoring, and red flags.

• Tirzepatide for Weight Loss

  Tirzepatide is a dual GIP/GLP-1 medication that supports weight loss; explore benefits, risks, and expectations.

• Sleeve Gastrectomy

  An in-depth guide to sleeve gastrectomy, including benefits, risks, and the recovery journey.

• Semaglutide for Weight Loss

  Semaglutide is a GLP-1 medication used for chronic weight management; learn dosing, benefits, and safety tips.

• Prescription Weight Loss Medications

  A guide to FDA-approved prescription weight loss medications, how they work, and how to compare options.

• Phentermine for Weight Loss

  Phentermine is a short-term prescription appetite suppressant; learn how it works, who it fits, and safety considerations.

• Ozempic Side Effects: Common Side Effects and Adverse Effects

  A clear guide to the common side effects of Ozempic—nausea, vomiting, diarrhea, constipation, abdominal pain, and decreased appetite—and the more serious adverse effects to watch for, including pancreatitis, gallbladder disease, and kidney injury.

• Medical Weight Loss Programs

  Physician-supervised weight loss programs combine medical monitoring, nutrition plans, and behavioral support.

• GLP-1 Weight Loss Medications Overview

  An overview of GLP-1 receptor agonists, how they support weight loss, and what to expect on treatment.

• Gastric Bypass Surgery

  Learn how Roux-en-Y gastric bypass works, who it is for, and what to expect before and after surgery.

• Gastric Balloon Procedures

  Gastric balloons are temporary devices that help reduce appetite and portion sizes; learn the pros and cons.

• Fat Burner Supplements

  Fat burner supplements promise faster metabolism, but evidence and safety vary widely; learn what to know.

• Bariatric Surgery Revision

  When initial bariatric surgery does not meet goals, revision procedures can address complications or weight regain.

• Bariatric Surgery Overview

  A comprehensive look at bariatric surgery options, eligibility, benefits, and long-term considerations.

• Adjustable Gastric Banding in 2026: Cost, Results, and Removal Options

  How the adjustable gastric band (lap band) works in 2026: typical 15–20% weight loss, cost, insurance, side-by-side comparison with sleeve and bypass, and what to do if you already have one.